Citadel Advisors’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Citadel Advisors’s Portfolio VCNX Stock Details VCNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	-$107	–	15326
2023 Q2	$107	Sell	1 -4	-80%	-$333	﹤0.01%	14220
2023 Q1	$439	Buy	+5	New	+$549	﹤0.01%	14495
2022 Q4	–	Hold	0	–	–	–	14775
2022 Q3	–	Sell	-102	Closed	-$23K	–	13826
2022 Q2	$23K	Sell	102 -77	-43%	-$19.7K	﹤0.01%	12353
2022 Q1	$50K	Buy	179 +75	+72%	+$20.7K	﹤0.01%	12788
2021 Q4	$23K	Buy	+104	New	+$37.5K	﹤0.01%	13556
2021 Q3	–	Sell	-184	Closed	-$108K	–	14847
2021 Q2	$108K	Buy	184 +6	+3%	+$3.17K	﹤0.01%	12855
2021 Q1	$111K	Buy	178 +35	+24%	+$22.5K	﹤0.01%	12384
2020 Q4	$62K	Sell	143 -184	-56%	-$77K	﹤0.01%	10489
2020 Q3	$122K	Buy	+327	New	+$357K	﹤0.01%	9152

Other funds holding VCNX

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tacita Capital Toronto, Ontario, Canada $169M AUM 24.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's VCNX Position: Q3 2023 in Review

Citadel Advisors sold out of Vaccinex, Inc. Common Stock (VCNX) in Q3 2023, closing a stake of 491 shares — an estimated $36.7K sold.

Citadel Advisors first reported a position in VCNX in Q3 2020 and held it in 11 quarters. The position peaked at $190K in Q1 2021. 18 funds tracked by Wall St. Rank hold VCNX as of Q3 2023.

Citadel Advisors reported no remaining Vaccinex, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 491 Vaccinex, Inc. Common Stock shares in Q3 2023, an estimated $36.7K.
Citadel Advisors first reported a position in Vaccinex, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
Citadel Advisors's Vaccinex, Inc. Common Stock position peaked at $190K in Q1 2021.
18 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.